List view / Grid view
13 April 2016 | By Victoria White, Digital Content Producer
A study has shown that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens...
12 April 2016 | By Victoria White, Digital Content Producer
HinsBet is a rapid-acting formulation of recombinant human insulin using BioChaperone, which is designed to accelerate insulin absorption...
12 April 2016 | By Victoria White, Digital Content Producer
Venclexta is the first FDA-approved treatment that targets the BCL-2 protein, which supports cancer cell growth and is overexpressed in many CLL patients...
12 April 2016 | By Victoria White, Digital Content Producer
Everolimus for advanced breast cancer, savuconazole for invasive aspergillosis and mucormycosis, and camellia sinensis for genital warts were all accepted...
12 April 2016 | By Victoria White, Digital Content Producer
The randomised, double-blind Phase II clinical study is designed to evaluate the safety and efficacy of Bekinda 12 mg in patients suffering from IBS-D...
11 April 2016 | By Victoria White, Digital Content Producer
Medical professionals, businesses and government officials from around the world have declared their commitment to fight antimicrobial resistance at ECCMID...
11 April 2016 | By Victoria White, Digital Content Producer
A current lack of data on outcomes in patients with IBD who have CDI means that appropriate choice of treatment strategy can be unclear...
11 April 2016 | By Victoria White, Digital Content Producer
TSC is the third indication that GW is targeting with Epidiolex, which includes four Phase III trials in Dravet syndrome and Lennox-Gastaut syndrome...
11 April 2016 | By Victoria White, Digital Content Producer
The first cancer patient in Europe has been scanned with a imaging technique that could enable doctors to see whether a drug is working within a day of starting treatment...
11 April 2016 | By Victoria White, Digital Content Producer
The FDA has granted a priority review for atezolizumab for the treatment of locally advanced or metastatic NSCLC that expresses the protein PD-L1...
8 April 2016 | By Victoria White, Digital Content Producer
The CHMP has recommended approval of a type II variation to include data from the TERRAIN trial of Xtandi (enzalutamide) versus bicalutamide...
8 April 2016 | By Victoria White, Digital Content Producer
A new study shows that levels of eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment...
8 April 2016 | By Victoria White, Digital Content Producer
The global treatment market for non-haematological cancers will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, according to GBI Research...
8 April 2016 | By Victoria White, Digital Content Producer
Tesaro will receive an upfront payment of $35 million, and is eligible to receive additional milestone payments of up to $415 million...
8 April 2016 | By Victoria White
AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial...
